NCT04727632: [18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial

NCT04727632
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Early Phase 1
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT04727632

Comments are closed.

Up ↑